BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201-214. [PMID: 26366103 DOI: 10.2147/tacg.s48605] [Cited by in Crossref: 105] [Cited by in F6Publishing: 114] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Sayk F, Grasshoff L. [Acute hepatic porphyrias]. Med Klin Intensivmed Notfmed 2023;118:21-9. [PMID: 36598516 DOI: 10.1007/s00063-022-00978-6] [Reference Citation Analysis]
2 Sreevalsakumar S, Nair C, Vellingiri B, Valsala Gopalakrishnan A. Porphyria. Genetic Syndromes 2023. [DOI: 10.1007/978-3-319-66816-1_1784-1] [Reference Citation Analysis]
3 Neeleman R, Musters K, Wagenmakers M, Mijnhout S, Friesema E, Sijbrands E, Langendonk J. Mortality in Pedigrees with Acute Intermittent Porphyria. Life (Basel) 2022;12. [PMID: 36556425 DOI: 10.3390/life12122059] [Reference Citation Analysis]
4 Kazamel M, Pischik E, Desnick RJ. Pain in acute hepatic porphyrias: Updates on pathophysiology and management. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1004125] [Reference Citation Analysis]
5 Vachiravit Sriprakoon, Chalisa Ittagornpunth, Nakorn Puapaiboon, Aekasit Bunyahathaipat, Punnapat Piriyanon, Sookkasem Khositseth, Kitiwan Rojnueangnit. Acute Intermittent Porphyria: Complete Phenotype in a Patient with p.Arg173Trp Variant in Thailand. Am J Case Rep 2022;23. [PMID: 36329616 DOI: 10.12659/AJCR.937695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Collaud E, Wittwer L, Minder A, Annoni J, Minder EI, Chabwine JN. Case Report: Variegate porphyria disclosed by post-gastric bypass complications and causing predominant painful sensorimotor axonal peripheral neuropathy. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.993453] [Reference Citation Analysis]
7 Wang B, Ventura P, Takase KI, Thapar M, Cassiman D, Kubisch I, Liu S, Sweetser MT, Balwani M. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study. Orphanet J Rare Dis 2022;17:327. [PMID: 36028858 DOI: 10.1186/s13023-022-02463-x] [Reference Citation Analysis]
8 Storjord E, Airila-Månsson S, Karlsen K, Madsen M, Dahl JA, Landsem A, Fure H, Ludviksen JK, Fjøse JØ, Dickey AK, Karlsen BO, Waage Nielsen E, Mollnes TE, Brekke OL. Dental and Periodontal Health in Acute Intermittent Porphyria. Life (Basel) 2022;12:1270. [PMID: 36013449 DOI: 10.3390/life12081270] [Reference Citation Analysis]
9 Kumar SR, Byrnes D, Mahfouz M, Rosenblatt J, Levy C. Time is of the Essence: Using Extended Hemin Treatment for a Case of Severe Acute Intermittent Porphyria. ACG Case Rep J 2022;9:e00827. [DOI: 10.14309/crj.0000000000000827] [Reference Citation Analysis]
10 Francesca G, Nicolli A, Colaiocco A, Di Pierro E, Graziadei G. Psychological Aspect and Quality of Life in Porphyrias: A Review. Diagnostics 2022;12:1193. [DOI: 10.3390/diagnostics12051193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ventura P, Ricci A. Givosiran for the treatment of acute hepatic porphyria. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2075848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Marcacci M, Ricci A, Cuoghi C, Marchini S, Pietrangelo A, Ventura P. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives. Orphanet J Rare Dis 2022;17:160. [PMID: 35392955 DOI: 10.1186/s13023-022-02314-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hersh WR, Cohen AM, Nguyen MM, Bensching KL, Deloughery TG. Clinical study applying machine learning to detect a rare disease: results and lessons learned. JAMIA Open 2022;5. [DOI: 10.1093/jamiaopen/ooac053] [Reference Citation Analysis]
14 Longo M, Paolini E, Meroni M, Dongiovanni P. Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution. Biomedicines 2022;10:648. [DOI: 10.3390/biomedicines10030648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Baumann K, Kauppinen R. Long-term follow-up of acute porphyria in female patients: Update of clinical outcome and life expectancy. Molecular Genetics and Metabolism Reports 2022;30:100842. [DOI: 10.1016/j.ymgmr.2022.100842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Sardh E, Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. J Intern Med. [DOI: 10.1111/joim.13443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sirch C, Khanna N, Frassetto L, Bianco F, Artero ML. Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report. World J Transplant 2022; 12(1): 8-14 [DOI: 10.5500/wjt.v12.i1.8] [Reference Citation Analysis]
18 Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peiró P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E; ENVISION Investigators. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int 2022;42:161-72. [PMID: 34717041 DOI: 10.1111/liv.15090] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
19 Ivanova M. Abdominal pain and other clinical and imaging features of porphyria. (Review. Own observations). Rus Jour of Pain 2022;20:52. [DOI: 10.17116/pain20222004152] [Reference Citation Analysis]
20 Poli A, Schmitt C, Moulouel B, Mirmiran A, Talbi N, Rivière S, Cerutti D, Bouchoule I, Faivre A, Grobost V, Douillard C, Duchêne F, Fiorentino V, Dupré T, Manceau H, Peoc'h K, Puy H, Lefebvre T, Gouya L. Givosiran in acute intermittent porphyria: A personalized medicine approach. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Puzikova АI, Litvin ЕА, Kildyushkin DА, Druy АЕ. Application of high-performance liquid chromatography in porphyrias diagnostics. Voprosy gematologii/onkologii i immunopatologii v pediatrii 2021;20:140-144. [DOI: 10.24287/1726-1708-2021-20-3-140-144] [Reference Citation Analysis]
22 Anderson KE, Desnick RJ, Stewart MF, Ventura P, Bonkovsky HL. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features that should Prompt Specific Diagnostic Testing. Am J Med Sci 2021:S0002-9629(21)00337-2. [PMID: 34606756 DOI: 10.1016/j.amjms.2021.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Vassiliou D, Sardh E, Harper P, Simon AR, Clausen VA, Najafian N, Robbie GJ, Agarwal S. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. Clin Pharmacol Ther 2021;110:1250-60. [PMID: 34510420 DOI: 10.1002/cpt.2419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Longo M, Paolini E, Meroni M, Duca L, Motta I, Fracanzani AL, Di Pierro E, Dongiovanni P. α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study. Diagnostics (Basel) 2021;11:1628. [PMID: 34573969 DOI: 10.3390/diagnostics11091628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Gilles A, Vermeersch S, Vermeersch P, Wolff F, Cotton F, Tilleux S, Cassiman D. Expert consensus statement on acute hepatic porphyria in Belgium. Acta Clin Belg 2021;:1-7. [PMID: 34369323 DOI: 10.1080/17843286.2021.1961056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Connolly MP, Kotsopoulos N, Vermeersch S, Patris J, Cassiman D. Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework. Orphanet J Rare Dis 2021;16:346. [PMID: 34348763 DOI: 10.1186/s13023-021-01966-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Pająk R, Mendela E, Będkowska N, Paprocka J. Update on Neuropathies in Inborn Errors of Metabolism. Brain Sci 2021;11:763. [PMID: 34201281 DOI: 10.3390/brainsci11060763] [Reference Citation Analysis]
28 Sachau J, Kersebaum D, Baron R, Dickenson AH. Unusual Pain Disorders - What Can Be Learned from Them? J Pain Res 2020;13:3539-54. [PMID: 33758536 DOI: 10.2147/JPR.S287603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Bustad HJ, Kallio JP, Vorland M, Fiorentino V, Sandberg S, Schmitt C, Aarsand AK, Martinez A. Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators. Int J Mol Sci 2021;22:E675. [PMID: 33445488 DOI: 10.3390/ijms22020675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
30 Haddad LA. Protein-Coding Genes. Human Genome Structure, Function and Clinical Considerations 2021. [DOI: 10.1007/978-3-030-73151-9_4] [Reference Citation Analysis]
31 Alm M, Andresen V, Ell C, Fibbe C, Fischbach W, Keller J, Frank Kipp P, May A, Miehlke S, Porschen R, Stallmach A, Weinke T, Aehling N, Alm M, Andresen V, Baumgart DC, Bertram F, Böhlig A, Bullmann C, Carstensen J, de Greck M, Ellerbeck W, Enders G, Fibbe C, Fischbach W, Fritz K, Gaus A, Gottschalk L, Grandt KD, Henniges U, Herta T, Jasper D, Keller J, Kschowak N, Lang K, Lange A, Layer P, Liedtke N, Luttermann J, Mancke L, Meier VS, Melle U, Menge D, Michaelis S, Nader S, Niedergassel T, Pachmann C, Porschen R, Rose S, Rosien U, Rössle M, Schellhorn M, Schnell O, Schulz S, Siegel J, Stein A, Szuba J, Teising S, Thiel S, Thomas-morr J, Tillmann H, Todt F, Veelken R, von Schassen H, Wölfel M, Wolf S, Wolgast V, Wübbolding C, Zimmermann K. Leber. Facharztwissen Gastroenterologie und Hepatologie 2021. [DOI: 10.1016/b978-3-437-21252-9.00011-0] [Reference Citation Analysis]
32 Quintero García MA, Martínez de la Vega Celorio A. Manejo de dolor con lidocaína en crisis aguda de porfiria en urgencias. Anales Médicos de la Asociación Médica del Centro Médico ABC 2021;66:214-217. [DOI: 10.35366/101670] [Reference Citation Analysis]
33 Nunnemann S, Uibel C, Budig P, Mäurer M. Acute intermittent porphyria (AIP) in a patient with celiac disease. Neurol Res Pract 2020;2:2. [PMID: 33324908 DOI: 10.1186/s42466-020-0049-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Castelbón Fernández F, Solares Fernandez I, Arranz Canales E, Enríquez de Salamanca Lorente R, Morales Conejo M. Protocol for patients with suspected acute porphyria. Revista Clínica Española (English Edition) 2020;220:592-6. [DOI: 10.1016/j.rceng.2019.10.011] [Reference Citation Analysis]
35 Swart G, Lim SS, Jude M. Acute intermittent porphyria presenting with posterior reversible encephalopathy syndrome (PRES) and abdominal pain. Pract Neurol 2020;20:486-488. [DOI: 10.1136/practneurol-2020-002599] [Reference Citation Analysis]
36 Zhao L, Wang X, Zhang X, Liu X, Ma N, Zhang Y, Zhang S. Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res 2020;9:205-16. [PMID: 33139979 DOI: 10.5582/irdr.2020.03089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Solares I, Tejedor M, Jericó D, Morales-Conejo M, Enríquez de Salamanca R, Fontanellas A, Tejedor-Jorge A. Management of hyponatremia associated with acute porphyria-proposal for the use of tolvaptan. Ann Transl Med 2020;8:1098. [PMID: 33145317 DOI: 10.21037/atm-20-1529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Cohen AM, Chamberlin S, Deloughery T, Nguyen M, Bedrick S, Meninger S, Ko JJ, Amin JJ, Wei AJ, Hersh W. Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria. PLoS One 2020;15:e0235574. [PMID: 32614911 DOI: 10.1371/journal.pone.0235574] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
39 Di Pierro E, Granata F. Nutrients and Porphyria: An Intriguing Crosstalk. Int J Mol Sci 2020;21:E3462. [PMID: 32422947 DOI: 10.3390/ijms21103462] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
40 Yang Y, Chen X, Wu H, Peng H, Sun W, He B, Yuan Z. A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome. Mol Med Rep 2020;22:516-24. [PMID: 32377710 DOI: 10.3892/mmr.2020.11117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stölzel U, Phillips JD, Kauppinen R, Langendonk JG, Desnick RJ, Deybach JC, Bonkovsky HL, Parker C, Naik H, Badminton M, Stein PE, Minder E, Windyga J, Bruha R, Cappellini MD, Sardh E, Harper P, Sandberg S, Aarsand AK, Andersen J, Alegre F, Ivanova A, Talbi N, Chan A, Querbes W, Ko J, Penz C, Liu S, Lin T, Simon A, Anderson KE. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology 2020;71:1546-58. [PMID: 31512765 DOI: 10.1002/hep.30936] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 20.7] [Reference Citation Analysis]
42 Aggarwal A, Kulshreshtha B. Catamenial Acute Intermittent Porphyria Managed with GnRH Analogues and Estrogen and Progesterone Add-back Therapy. J Pediatr Adolesc Gynecol 2020;33:432-4. [PMID: 32113877 DOI: 10.1016/j.jpag.2020.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Cox TM. The porphyrias. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0231] [Reference Citation Analysis]
44 Baravelli CM, Aarsand AK, Sandberg S, Tollånes MC. Sick leave, disability, and mortality in acute hepatic porphyria: a nationwide cohort study. Orphanet J Rare Dis 2020;15:56. [PMID: 32085780 DOI: 10.1186/s13023-019-1273-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
45 Blaylock B, Epstein J, Stickler P. Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin. J Med Econ 2020;23:537-45. [PMID: 31999204 DOI: 10.1080/13696998.2020.1724118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Fatima SA, Jurair H, Abbas Q, Rehman AJ. Paediatric porphyria and human hemin: a treatment challenge in a lower middle income country. BMJ Case Rep 2020;13:e232236. [PMID: 31919062 DOI: 10.1136/bcr-2019-232236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Guo Y, Zhao J, Wang H, Liu S, Huang T, Chang G. Metabolic Disorder-Related Hypertension. Secondary Hypertension 2020. [DOI: 10.1007/978-981-15-0591-1_15] [Reference Citation Analysis]
48 Frank EL, Parnás ML. The porphyrias: fundamentals and laboratory assessment. Contemporary Practice in Clinical Chemistry 2020. [DOI: 10.1016/b978-0-12-815499-1.00049-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Esteve-Valverde E, Tapiz-Reula A, Ruiz D, Alijotas-Reig J. Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. Rheumatol Int 2020;40:777-83. [PMID: 31865445 DOI: 10.1007/s00296-019-04500-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Spiritos Z, Salvador S, Mosquera D, Wilder J. Acute Intermittent Porphyria: Current Perspectives And Case Presentation. Ther Clin Risk Manag 2019;15:1443-51. [PMID: 31908464 DOI: 10.2147/TCRM.S180161] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
51 Bustad HJ, Toska K, Schmitt C, Vorland M, Skjærven L, Kallio JP, Simonin S, Letteron P, Underhaug J, Sandberg S, Martinez A. A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria. Mol Ther 2020;28:677-89. [PMID: 31810863 DOI: 10.1016/j.ymthe.2019.11.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
52 Silva CD, Mateus JE, Teles C, Vaio T. Acute intermittent porphyria: analgesia can be dangerous. BMJ Case Rep 2019;12:e231133. [PMID: 31570358 DOI: 10.1136/bcr-2019-231133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Gheorghe GS, Hodorogea AS, Gheorghe ACD, Zaharia OIR, Neacsu O, Nanea IT, Ciobanu A. Particular etiology in a case of peripheral tetraparesis. Clin Case Rep 2019;7:1062-6. [PMID: 31110746 DOI: 10.1002/ccr3.2157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, Rajagopal VM, Als TD, T Nguyen H, Girdhar K, Boocock J, Roussos P, Fromer M, Kramer R, Domenici E, Gamazon ER, Purcell S, Demontis D, Børglum AD, Walters JTR, O'Donovan MC, Sullivan P, Owen MJ, Devlin B, Sieberts SK, Cox NJ, Im HK, Sklar P, Stahl EA; CommonMind Consortium., Schizophrenia Working Group of the Psychiatric Genomics Consortium., iPSYCH-GEMS Schizophrenia Working Group. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nat Genet 2019;51:659-74. [PMID: 30911161 DOI: 10.1038/s41588-019-0364-4] [Cited by in Crossref: 120] [Cited by in F6Publishing: 126] [Article Influence: 30.0] [Reference Citation Analysis]
55 Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, Howe DL, Hungate JR, Kim JB, Agarwal S, Marquis P. Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations. Patient 2018;11:527-37. [PMID: 29915990 DOI: 10.1007/s40271-018-0319-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
56 Yarra P, Faust D, Bennett M, Rudnick S, Bonkovsky HL. Benefits of prophylactic heme therapy in severe acute intermittent porphyria. Mol Genet Metab Rep 2019;19:100450. [PMID: 30733921 DOI: 10.1016/j.ymgmr.2019.01.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
57 Andreychenko SA, Sukonnikov TA, Bychinin MV, Klypa TV. Difficulties in the diagnosis of acute porphyria: case report. Anesteziologiya i Reanimatologiya 2019. [DOI: 10.17116/anaesthesiology201903190] [Reference Citation Analysis]
58 Iwai M, Kitamura A, Isomoto H, Horie Y, Tsui WMS. Metabolic Disorders in the Liver. Diagnosis of Liver Disease 2019. [DOI: 10.1007/978-981-13-6806-6_12] [Reference Citation Analysis]
59 Disorders of the Human Circulatory System. Examining the Causal Relationship Between Genes, Epigenetics, and Human Health 2019. [DOI: 10.4018/978-1-5225-8066-9.ch013] [Reference Citation Analysis]
60 Teschke R. Aliphatic Halogenated Hydrocarbons: Report and Analysis of Liver Injury in 60 Patients. J Clin Transl Hepatol 2018;6:350-61. [PMID: 30637211 DOI: 10.14218/JCTH.2018.00040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
61 Chiabrando D, Fiorito V, Petrillo S, Tolosano E. Unraveling the Role of Heme in Neurodegeneration. Front Neurosci 2018;12:712. [PMID: 30356807 DOI: 10.3389/fnins.2018.00712] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
62 Varshney GA, Saini PA, Ghure U. A rare case of acute intermittent porphyria with ichthyosis vulgaris in a young boy. J Family Med Prim Care 2018;7:261-3. [PMID: 29915773 DOI: 10.4103/jfmpc.jfmpc_141_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
63 Nunnemann S. Enzymdefekt mit schweren Folgen. DNP 2018;19:26-30. [DOI: 10.1007/s15202-018-1986-6] [Reference Citation Analysis]
64 Martin P. Schmerz und Epilepsie: Eine klinisch-neuroanatomisch-pathophysiologische Übersicht. Schmerz 2018;32:301-20. [DOI: 10.1007/s00482-018-0298-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
65 Teschke R. Liver Injury by Carbon Tetrachloride Intoxication in 16 Patients Treated with Forced Ventilation to Accelerate Toxin Removal via the Lungs: A Clinical Report. Toxics 2018;6:E25. [PMID: 29702608 DOI: 10.3390/toxics6020025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
66 Edel Y, Mamet R. Porphyria: What Is It and Who Should Be Evaluated? Rambam Maimonides Med J 2018;9. [PMID: 29553924 DOI: 10.5041/RMMJ.10333] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
67 Tabaro I, Reimondo G, Osella G, Aurizi C, Caraci P, Barbieri L, Giachino DF, Sirchia F, Terzolo M. Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis. Endocrine 2018;61:403-6. [PMID: 29516370 DOI: 10.1007/s12020-018-1569-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Khadilkar SV, Yadav RS, Patel BA. Porphyrias. Neuromuscular Disorders 2018. [DOI: 10.1007/978-981-10-5361-0_43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Kowar M, Jacobs AH. Wechselnde Vigilanz und Fremdaggressivität bei einer 89‑jährigen Patientin. Internist 2018;59:97-101. [DOI: 10.1007/s00108-017-0270-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 . Leber. Facharzt Gastroenterologie 2018. [DOI: 10.1016/b978-3-437-21251-2.00010-3] [Reference Citation Analysis]
71 Júnior VRS, Lemos VMV, Feitosa IML, Florencio R, Correia CWB, Fontes LBC, Costa MFH, Correia MCB. Effect of Menstrual Cycle on Acute Intermittent Porphyria. Child Neurol Open 2017;4:2329048X17736170. [PMID: 29094055 DOI: 10.1177/2329048X17736170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
72 Mejia B JJ, Caballero D, Villanueva J, Dueñas Castell CR. Porfirias agudas: enfoque diagnóstico y terapéutico. Acta Colombiana de Cuidado Intensivo 2017;17:276-294. [DOI: 10.1016/j.acci.2017.10.002] [Reference Citation Analysis]
73 Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, Phillips JD, Desnick RJ; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Acute hepatic porphyrias: Recommendations for evaluation and long-term management. Hepatology 2017;66:1314-22. [PMID: 28605040 DOI: 10.1002/hep.29313] [Cited by in Crossref: 84] [Cited by in F6Publishing: 88] [Article Influence: 14.0] [Reference Citation Analysis]
74 Žebeljan I, Anzeljc V, Serdinšek T, Mujezinović F. A case of previously undiagnosed acute intermittent porphyria in a 34-year-old primigravida with gestational diabetes mellitus. Case Reports in Perinatal Medicine 2017;6. [DOI: 10.1515/crpm-2017-0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Kumar S, Bhalla A, Sharma N, Dhibar DP, Kumari S, Varma S. Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India. Ann Indian Acad Neurol 2017;20:263-9. [PMID: 28904459 DOI: 10.4103/aian.AIAN_91_17] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
76 Dhital R, Basnet S, Poudel DR, Bhusal KR. Acute intermittent porphyria: a test of clinical acumen. J Community Hosp Intern Med Perspect 2017;7:100-2. [PMID: 28638573 DOI: 10.1080/20009666.2017.1317535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Attarian S, Yu C, Anderson KE, Friedman EW. Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure. Blood Adv 2017;1:915-7. [PMID: 29296735 DOI: 10.1182/bloodadvances.2017005660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
78 Ajayi T, Ward R, Summers B, Byrns J, Kappus M, Choi S, Wilder J. Pathophysiology, Pharmacology and Treatment of Acute Intermittent Porphyria: A Patient Case Description and Recommendations from the Current Literature. Journal of Exploratory Research in Pharmacology 2017;2:49-53. [DOI: 10.14218/jerp.2016.00022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
79 Lei LJ, Guo YH, Yang Y. Recurrent abdominal pain as principal clinical manifestation of acute intermittent porphyria: A case report and literature review. Shijie Huaren Xiaohua Zazhi 2017; 25(12): 1128-1134 [DOI: 10.11569/wcjd.v25.i12.1128] [Reference Citation Analysis]
80 Kürten V, Neumann NJ, Frank J. [Diagnosis of the porphyrias : From A (as in aminolevulinic acid) to Z (as in zinc protoporphyrin)]. Hautarzt 2016;67:201-6. [PMID: 26743052 DOI: 10.1007/s00105-015-3741-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
81 Mohanlal S, Ghildiyal RG, Kondekar A, Wade P, Sinha R. A Commonly Missed Well Known Entity- Acute Intermittent Porphyria: A Case Report. J Clin Diagn Res 2016;10:SD01-2. [PMID: 27891417 DOI: 10.7860/JCDR/2016/20464.8609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
82 Arora S, Young S, Kodali S, Singal AK. Hepatic porphyria: A narrative review. Indian J Gastroenterol 2016;35:405-18. [PMID: 27796941 DOI: 10.1007/s12664-016-0698-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
83 Norton J, Hymers C, Stein P, Jenkins JM, Bew D. Acute Porphyria Presenting as Major Trauma: Case Report and Literature Review. J Emerg Med 2016;51:e115-22. [PMID: 27624508 DOI: 10.1016/j.jemermed.2016.06.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Smeets T, van Hunsel F. Red-Brown Urine Discolouration in Two Patients Taking Mesalamine. Drug Saf Case Rep 2016;3:6. [PMID: 27747686 DOI: 10.1007/s40800-016-0029-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Naik H, Stoecker M, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study. Mol Genet Metab 2016;119:278-83. [PMID: 27595545 DOI: 10.1016/j.ymgme.2016.08.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
86 García-Morillo JS, González-Estrada A, Rodriguez-Suarez S. [Influence of long-term treatment with hemin in the development of chronic renal failure in acute intermittent porphyria]. Med Clin (Barc). 2016;146:373-374. [PMID: 26723937 DOI: 10.1016/j.medcli.2015.10.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
87 García-morillo JS, González-estrada A, Rodriguez-suarez S. Influence of long-term treatment with hemin in the development of chronic renal failure in acute intermittent porphyria. Medicina Clínica (English Edition) 2016;146:373-374. [DOI: 10.1016/j.medcle.2016.06.009] [Reference Citation Analysis]